Antithrombin reduces monocyte and neutrophil CD11b up regulation in addition to blocking platelet activation during extracorporeal circulation

Transfusion

Volumn 46, Issue 7, 2006, Pages 1130-1137

  Rinder, Christine S ^a   Rinder, Henry M ^a   Smith, Michael J ^a   Fitch, Jane C K ^a   Tracey, Jayne B ^a   Chandler, Wayne L ^a   Rollins, Scott A ^a   Smith, Brian R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; CD11B ANTIGEN; COMPLEMENT COMPONENT C3A; COMPLEMENT MEMBRANE ATTACK COMPLEX; FIBRIN; FIBRINOPEPTIDE A; HEPARIN; LEUKOCYTE ELASTASE; PADGEM PROTEIN; PROTHROMBIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPLEMENT ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; ENZYME RELEASE; EXTRACORPOREAL CIRCULATION; HEART SURGERY; HUMAN; HUMAN TISSUE; INFLAMMATION; MONOCYTE; NEUTROPHIL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; UPREGULATION;

ANTIGENS, CD11B; ANTITHROMBIN III; EXTRACORPOREAL CIRCULATION; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MONOCYTES; NEUTROPHILS; PLATELET AGGREGATION INHIBITORS; UP-REGULATION;

EID: 33746565874     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00861.x     Document Type: Article

References (51)

1. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001;103:1718-20.
2. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thor Surg 2001;71:745-54.
3. Greilich PE, Brouse CF, Rinder CS, et al. Effects of epsilon aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology 2004;100:225-33.
4. Smith BR, Rinder HM, Rinder CS. Cardiopulmonary bypass. In: Michaelson A, editor. Platelets. New York: Academic Press; 2002. p. 727-34.
5. Rinder CS, Mathew JP, Rinder HM, Smith BR. Neutrophil activation and CD11b upregulation during cardiopulmonary bypass is associated with greater postoperative renal injury. Ann Thorac Surg 2003;75:899-905.
6. Fontes M, Mathew JP, Rinder HM, et al. Atrial fibrillation after cardiopulmonary bypass is associated with monocyte activation. Anesth Analg 2005;101:17-23.
7. Levy JH, Montes F, Szlam F, et al. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000;90:1076-9.
8. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000;70:873-7.
9. Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistent patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;130:107-13.
10. Dickneite G, Leithauser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol 1999;19:1566-72.
11. Ostrovsky L, Woodman RC, Payne D, et al. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997;96:2302-10.
12. Dunzendorfer S, Kaneider N, Rabensteiner A, et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by serpin antithrombin III. Blood 2001;97:1079-85.
13. Zuo XJ, Okada Y, Nicolaidou E, et al. Antithrombin III inhibits T and B lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. Transplant Proc 1999;31:847-8.
14. Ranucci M, Frigiola A, Menicanti L, et al. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005;33:355-60.
15. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993;106:1-9.
16. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96:1564-72.
17. Rinder CS, Rinder HM, Johnson K, et al. Role of C3 cleavage in monocyte activation during extracorporeal circulation. Circulation 1999;100:553-8.
18. Rinder CS, Rinder HM, Smith MJ, et al. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J Cardiovasc Thorac Surg 1999;118:460-6.
19. Rinder CS, Bonan JT, Rinder HM, et al. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992;79:1201-5.
20. Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999;100:2499-506.
21. Van Norman GA, Gernsheimer T, Chandler WL, et al. Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired antithrombin III deficiency. J Cardiothor Vasc Anesth 1997;11:760-3.
22. Wiedermann CJ. Improvement in coagulation markers with anti-thrombin - beeficial in severe sepsis? Crit Care Med 2004;32:1968-9.
23. Warren BL, Eid A, Singer P, et al. High dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78.
24. Hoffmann JN, Muhlbayer D, Jochum M, et al. Effect of long term and high dose antithrombin supplementation on coagulation and fibrinolysis in patients with sever sepsis. Crit Care Med 2004;32:1851-9.
25. Inthorn D, Hoffman JN, Hartl WH, et al. Effect on antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998;10:90-6.
26. Wachtfogel YT, Kettner C, Hack CE, et al. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation. Thromb Haemost 1998;80:686-91.
27. Hou L, Howells GL, Kapas S, et al. The protease-activated receptors and their cellular expression and function in blood-related cells. Br J Haematol 1998;101:1-9.
28. Kaneider NC, Reinisch CM, Dunzendorfer S, Romisch J, Wiedermann CJ. Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 2002;115:227-36.
29. Suk K, Cha S. Thrombin-induced interleukin-8 production and its regulation by interferon-gamma and prostaglandin E2 in human monocytic U937 cells. Immunol Lett 1999;67:223-7.
30. Naldini A, Sower L, Bocci V, et al. Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation. J Cell Physiol 1998;177:76-84.
31. Srivastava KD, Magazine HI. Thrombin receptor activation inhibits monocyte spreading by induction of ET(B) receptor-coupled nitric oxide release. J Immunol 1998;161:5039-44.
32. Sower LE, Froelich CJ, Allegretto N, et al. Extracellular activities of human granzyme A: monocyte activation by granzyme A versus alpha-thrombin. J Immunol 1996;156:2585-90.
33. Hoffman M, Cooper ST. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1β by two distinct mechanisms. Blood Cells Mol Dis 1995;21:156-67.
34. Hoffman M, Church FC. Response of blood leukocytes to thrombin receptor peptides. J Leukoc Biol 1993;54:145-51.
35. Johnson K, Choi Y, DeGroot E, et al. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998;160:5130-5.
36. Colotta F, Sciacca FL, Sironi M, et al. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994;144:975-85.
37. Oelschlager C, Romisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002;99:4015-20.
38. Uchiba M, Okajima K, Kaun C, Wojta J, Binder BR. Inhibition of the endothelial cell activation by antithrombin in vitro. Thromb Haemost 2004;92:1420-7.
39. Souter PJ, Thomas S, Hubbard AR, et al. Antithrombin inhibits lipopolysaccharide induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001;29:134-9.
40. Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997;95:2387-94.
41. Aiura K, Clark BD, Dinarello CA, et al. Interaction with autologous platelets multiplies interleukin-1 and tumor necrosis factor production in mononuclear cells. J Infect Dis 1997;175:123-9.
42. Jy W, Mao WW, Horstman L, et al. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis 1995;21:217-31.
43. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 2001;287:42-6.
44. Jenkins AL, Howells GL, Scott E, et al. The response to thrombin of human neutrophils: evidence for two novel receptors. J Cell Sci 1995;108:3059-66.
45. Woodman RC, Teoh D, Payne D, et al. Thrombin and leukocyte recruitment in endotoxemia. Am J Physiol Heart Circ Physiol 2000;279:H1338-45.
46. Hackert T, Werner J, Uhl W, et al. Reduction of ischemia/ reperfusion injury by antithrombin III after experimental pancreas transplantation. Am J Surg 2005;189:92-7.
47. Isobe H, Okajima K, Uchiba M, Harada N, Okabe H. Antithrombin prevents endotoxin-induced hypotension by inhibiting the induction of nitric oxide synthase in rats. Blood 2002;99:1638-45.
48. Mizutani A, Okajima K, Uchiba M, et al. Antithrombin reduces ischemia/reperfusion induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003;101:3029-36.
49. Weiler JM, Linhardt RJ. Antithrombin III regulates complement activity in vitro. J Immunol 1991;146:3889-94.
50. Musso T, Deaglio S, Franco L, et al. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol 2001;69:605-12.
51. Deszo EL, Brake DK, Cengel KA, et al. CD45 negatively regulates monocytic cell differentiation by inhibiting phorbol 12-myristate 13-acetate-dependent activation and tyrosine phosphorylation of protein kinase CA. J Biol Chem 2001;276:10212-7.